BIOMAT Database Logo BIOMAT Database Logo

Synthesis and biological evaluation of conformationally constrained analogues of the antitubercular agent ethambutol. 2007

Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Laboratoire de Synthèse et Physicochimie de Molécules d'Intérêt Biologique, UMR 5068, Université Paul Sabatier, 31062 Toulouse, Cedex 9, France.

Three (S)-prolinol-derived conformationally restricted analogues of the antitubercular agent ethambutol were prepared and tested against Mycobacterium tuberculosis.

UI MeSH Term Description Entries
D007097 Imines Organic compounds containing a carbon-nitrogen double bond where a NITROGEN atom can be attached to HYDROGEN or an alkyl or aryl group. Imine
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Nitrogen-bridged conformationally constrained etorphine analogues. Synthesis and biological evaluation.
November 1987, Journal of medicinal chemistry,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Synthesis of conformationally constrained lysine analogues.
June 2006, The Journal of organic chemistry,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Design and synthesis of conformationally constrained glucagon analogues.
May 2000, Journal of medicinal chemistry,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Synthesis and biological evaluation of conformationally restricted Gabapentin analogues.
August 1999, Bioorganic & medicinal chemistry letters,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Synthesis and biological evaluation of bombesin constrained analogues.
June 2000, Journal of medicinal chemistry,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Synthesis and biological evaluation of flexible and conformationally constrained LpxC inhibitors.
September 2013, Organic & biomolecular chemistry,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
November 2004, Journal of medicinal chemistry,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Solid-phase synthesis and biochemical evaluation of conformationally constrained analogues of deglycobleomycin A5.
November 2003, Bioorganic & medicinal chemistry,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors.
June 2009, Organic letters,
Vanessa Faugeroux, and Yves Génisson, and Yahya Salma, and Patricia Constant, and Michel Baltas
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
October 2013, ACS medicinal chemistry letters,
Copied contents to your clipboard!